AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9255764
Drug: Skinner herpes
RxNorm normalized name: herpesvirus 2, human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skinner herpes simplex vaccine (NFU.Ac.HSV‐1(S‐)MRC)
Trial: 9255764
Drug: Skinner herpes
RxNorm normalized name: herpesvirus 2, human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skinner herpes simplex vaccine (NFU.Ac.HSV‐1(S‐)MRC
Trial: 7685425
Drug: Verapamil (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (80 mg, four doses orally starting the night before ESWL)
Trial: 28370401
Drug: High-dose cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cyclophosphamide (2 g/m2 daily on days 1 and 2) plus G-CSF and pre-emptive/rescue plerixafor
Trial: 28370401
Drug: High-dose cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cyclophosphamide (2 g/m2 daily on days 1 and 2) plus G-CSF
Trial: 28370401
Drug: High-dose cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cyclophosphamide (2 g/m2 daily on days 1 and 2)
Trial: 21716073
Drug: Dolutegravir 2
RxNorm normalized name: dolutegravir 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolutegravir 2 mg
Trial: 19194375
Drug: Combined cholinergic
RxNorm normalized name: PARASYMPATHOMIMETICS (CHOLINERGICS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined cholinergic receptor blockade (scopolamine 4 microg/kg bodyweight intravenously and mecamylamine 5 mg orally)
Trial: 19194375
Drug: Combined cholinergic
RxNorm normalized name: PARASYMPATHOMIMETICS (CHOLINERGICS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined cholinergic receptor blockade
Trial: 16704676
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of splinting, tendon‐ and nerve‐gliding exercises
Trial: 16704676
Drug: Ultrasound treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound treatment in combination with splinting
Trial: 16704676
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ultrasound, splinting, tendon‐ and nerve‐gliding exercises
Trial: 16704676
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of splinting, exercise and ultrasound therapy
Trial: 15679252
Drug: Concurrent chemoradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiation with surgery
Trial: 15679252
Drug: Concurrent chemoradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiation without surgery
Trial: 11316542
Drug: Hfx RT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hfx RT with daily carboplatin/etoposide (50 mg each)
Trial: 11316542
Drug: Hfx RT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hfx RT with daily carboplatin/etoposide (30 mg each) and weekend carboplatin/etoposide (100 mg each)
Trial: 9027276
Drug: Allopurinol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (20 mg/kg/day, three 100-mg tablets four times daily for 28 days)
Trial: 9027276
Drug: Placebo (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (three placebo tablets four times daily for 28 days)
Trial: 9027276
Drug: Glucantime (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucantime (20 mg of intramuscular antimony/kg per day for 20 days)
Trial: 8276046
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of SDZ MKS 492 (40 mg)
Trial: 8276046
Drug: Inhaled SDZ
RxNorm normalized name: SDZ MSL 109
DrugBank: Sevirumab (DB17771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled SDZ MKS 492 (12 mg)
Trial: 8276046
Drug: Inhaled SDZ
RxNorm normalized name: SDZ MSL 109
DrugBank: Sevirumab (DB17771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled SDZ MKS 492 (10 mg and 20 mg)
Trial: 8276046
Drug: Inhaled SDZ
RxNorm normalized name: SDZ MSL 109
DrugBank: Sevirumab (DB17771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled SDZ MKS 492
Trial: 31919695
Drug: Parent-Based Treatment
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent-Based Treatment (PBT)
Trial: 29716471
Drug: Standard-mother-infant treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-mother-infant treatment (TAU)
Trial: 26935334
Drug: Levofloxacin inhalation
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin inhalation solution (LIS) 240mg twice daily for 28 days
Trial: 26935334
Drug: Levofloxacin inhalation
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin inhalation solution (LIS)
Trial: 20378601
Drug: Sitaxsentan (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitaxsentan (100 mg·day(‐1) for 7 days)
Trial: 14640991
Drug: GH (0.88+/‐0.13
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH (0.88+/‐0.13 mg)
Trial: 14640991
Drug: GH+acipimox 250
RxNorm normalized name: acipimox 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH+acipimox 250 mg b.i.d.
Trial: 8853083
Drug: 6 to
RxNorm normalized name: vitamin B6 Topical Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 to 7% sevoflurane in 66% nitrous oxide/28% oxygen by face mask until tracheal intubation (treatment 1)
Trial: 8853083
Drug: 6 to
RxNorm normalized name: vitamin B6 Topical Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 to 7% sevoflurane without nitrous oxide to tracheal intubation (treatment 2)
Trial: 8853083
Drug: 6 to
RxNorm normalized name: vitamin B6 Topical Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 to 7% sevoflurane in 66% nitrous oxide/28% oxygen by face mask until laryngeal mask airway insertion (treatment 3)
Trial: 1535877
Drug: High-dose ionic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ionic contrast medium (diatrizoate sodium)
Trial: 1535877
Drug: High-dose nonionic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose nonionic contrast medium (iohexol)
Trial: 1535877
Drug: Low-dose nonionic
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose nonionic contrast medium (iohexol)
Trial: 6526201
Drug: Isosorbide Dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide Dinitrate Ointment (ISDN-O): 300 mg daily
Trial: 30878411
Drug: Low-dose nebulized
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose nebulized epinephrine (0.1 mg/kg; maximum 1 mg)
Trial: 30878411
Drug: Conventional dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dose nebulized epinephrine (0.5 mg/kg; maximum 5 mg)
Trial: 26957110
Drug: GS-9857 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GS-9857 (100 mg once daily for 3 days)
Trial: 26957110
Drug: GS-9857 (50-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GS-9857 (50-300 mg once daily for 3 days)
Trial: 18059586
Drug: Antioxidant supplementation
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant supplementation (400 IU vitamin E + 1 g vitamin C)
Trial: 12794024
Drug: Pentoxifyllin (PTX)
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifyllin (PTX) 30 mg/kg/day
Trial: 10695096
Drug: nifedipine GITS
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: nifedipine GITS 20 mg once daily
Trial: 12239234
Drug: Fosinopril (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fosinopril (20 mg)
Trial: 25662474
Drug: Inpatient treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inpatient treatment (2-day admission)
Trial: 17577468
Drug: Intravenous/oral linezolid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous/oral linezolid
Trial: 7698835
Drug: 0.25% prednicarbate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25% prednicarbate cream used twice daily over 5 days
Trial: 7698835
Drug: 0.25% prednicarbate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25% prednicarbate cream with didecyldimethylammoniumchloride
Trial: 2937812
Drug: Ciprofloxacin 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 1,000 mg
Trial: 2937812
Drug: Ciprofloxacin (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (all doses)
Trial: 27814869
Drug: Neurodynamic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neurodynamic treatment (four sessions over two weeks comprising passive lumbar foramen opening and neurodynamic sliders plus home exercises)
Trial: 25357122
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of spraying and eliminating dogs
Trial: 23837404
Drug: Deworming and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deworming and weekly iron supplementation for 6 months
Trial: 10933355
Drug: Ramipril (5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril (5-10 mg daily)
Trial: 9024334
Drug: Cholinergic agents
RxNorm normalized name: ANTICHOLINERGIC AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholinergic agents (cholinesterase inhibitors)
Trial: 9024334
Drug: Antioxidants, monoamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidants, monoamine oxidase‐B inhibitors, cholinesterase inhibitors, anti‐inflammatory agents
Trial: 9024334
Drug: Drugs that
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs that improve cognition
Trial: 1316061
Drug: Lomefloxacin 400
RxNorm normalized name: lomefloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lomefloxacin 400 mg orally 2‐6 hours prior to surgery
Trial: 1316061
Drug: Cefotaxime 1
RxNorm normalized name: cefotaxime 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime 1 g intravenously or intramuscularly 30‐90 minutes preoperatively
Trial: 7462679
Drug: 8-methoxypsoralen (8-MOP)
RxNorm normalized name: 8-methoxypsoralen
DrugBank: Methoxsalen (DB00553)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8-methoxypsoralen (8-MOP) 0.3 mg/kg
Trial: 7462679
Drug: 8-methoxypsoralen (8-MOP)
RxNorm normalized name: 8-methoxypsoralen
DrugBank: Methoxsalen (DB00553)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8-methoxypsoralen (8-MOP) 0.6 mg/kg
Trial: 7462679
Drug: 8-methoxypsoralen (8-MOP)
RxNorm normalized name: 8-methoxypsoralen
DrugBank: Methoxsalen (DB00553)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8-methoxypsoralen (8-MOP) 0.9 mg/kg
Trial: 28741653
Drug: Chloral hydrate
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloral hydrate syrup 50 mg.kg-1
Trial: 28741653
Drug: Intranasal saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal saline spray (control)
Trial: 28741653
Drug: Intranasal dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal dexmedetomidine spray 3 μg.kg-1
Trial: 28741653
Drug: Chloral hydrate
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloral hydrate syrup and placebo spray
Trial: 25321659
Drug: Omega-3 supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 supplements (4.0 g/d eicosapentaenoic acid and 2.0 g/d docosahexaenoic acid)
Trial: 19303968
Drug: Pulsatile intravenous
RxNorm normalized name: PULSATILLA PRATENSIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsatile intravenous insulin therapy
Trial: 17217712
Drug: xuezhikang (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: xuezhikang (1200 mg/d)
Trial: 14513420
Drug: Antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy regimen 1
Trial: 14513420
Drug: Antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy regimen 2
Trial: 14513420
Drug: Antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy regimen 3
Trial: 6750781
Drug: Oral zinc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral zinc sulphate
Trial: 26029816
Drug: Inactivated hepatitis
RxNorm normalized name: Inactivated hepatitis A vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated hepatitis A vaccine (Havrix™, GSK, Belgium)
Trial: 19909979
Drug: Fludrocortisone (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludrocortisone (0.2 mg/d)
Trial: 18227107
Drug: Treatment effects
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment effects in trials with allocation concealment
Trial: 15840761
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of diazepam
Trial: 12574578
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen therapy (HBO) at 2.5 ATA for 60 minutes
Trial: 12574578
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment at 1.14 ATA
Trial: 10707873
Drug: rHuIL-12 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rHuIL-12 (all doses)
Trial: 31171016
Drug: Pomegranate juice
RxNorm normalized name: pomegranate juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pomegranate juice (125 mL taken twice daily for 12 weeks)
Trial: 31171016
Drug: Placebo (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (125 mL taken twice daily for 12 weeks)
Trial: 20934829
Drug: Intramuscular piroxicam
RxNorm normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular piroxicam (20 mg)
Trial: 11410192
Drug: Deltamethrin insecticide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deltamethrin insecticide treatment applied to livestock during the malaria transmission seasons.
Trial: 11410192
Drug: Deltamethrin insecticide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deltamethrin insecticide treatment applied to livestock.
Trial: 11410192
Drug: Deltamethrin insecticide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deltamethrin insecticide treatment applied to livestock in a highly endemic settlement.
Trial: 9404682
Drug: Lithium carbonate
RxNorm normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lithium carbonate treatment with diet only (Group I)
Trial: 9404682
Drug: Lithium carbonate
RxNorm normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lithium carbonate treatment with oral hypoglycemic agents (OHA) (Group II)
Trial: 9404682
Drug: Lithium carbonate
RxNorm normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lithium carbonate treatment with insulin (Group III)
Trial: 8234998
Drug: Nitroglycerin patches
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin patches (10 mg/day)
Trial: 8234998
Drug: Continuous treatment
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous treatment with nitroglycerin patches
Trial: 8234998
Drug: Intermittent treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent treatment with nitroglycerin patches
Trial: 3548602
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose steroid regimen
Trial: 25047497
Drug: Lobeglitazone 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lobeglitazone 0.5 mg with ketoconazole (9 doses of 200 mg pretreatment twice daily)
Trial: 25047497
Drug: Lobeglitazone 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lobeglitazone 0.5 mg without ketoconazole
Trial: 22418661
Drug: MF59-adjuvanted vaccines
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF59-adjuvanted vaccines
Trial: 22418661
Drug: Nonadjuvanted vaccines
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonadjuvanted vaccines
Trial: 22418661
Drug: Vaccine with
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine with 7.5 µg antigen and full dose of MF59
Trial: 18025250
Drug: Atomoxetine (10-week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atomoxetine (10-week treatment)
Trial: 11303372
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose interleukin-2 (IL-2) therapy, 720,000 IU/kg per dose i.v. in 15 minutes, administered in bolus for 2 weeks with a 1 week rest interval.
Trial: 11303372
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose interleukin-2 (IL-2) therapy with prior autologous vaccines.
Trial: 1446996
Drug: Propranolol treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol treatment for 4 to 6 weeks after a 2-week placebo phase
Trial: 2870353
Drug: LHRH (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LHRH (1.2 mg/day intranasally)
Trial: 2870353
Drug: LHRH and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LHRH and human chorionic gonadotropin (before treatment)
Trial: 28661264
Drug: Solifenacin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solifenacin (5 mg once daily for 15 days)
Trial: 25617983
Drug: alglucosidase alfa
RxNorm normalized name: Alglucosidase Alfa
DrugBank: Alglucosidase alfa (DB01272)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: alglucosidase alfa 20 mg/kg/week
Trial: 25617983
Drug: alglucosidase alfa
RxNorm normalized name: Alglucosidase Alfa
DrugBank: Alglucosidase alfa (DB01272)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: alglucosidase alfa 40 mg/kg/2 weeks
Trial: 25617983
Drug: standard ERT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard ERT (alglucosidase alfa 20 mg/kg/2 weeks)
Trial: 19538690
Drug: Disorder-specific psychotherapies
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disorder-specific psychotherapies (CBT, interpersonal, family, and group therapies)
Trial: 19538690
Drug: Adjunctive psychotherapies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive psychotherapies
Trial: 17426802
Drug: Cisatracurium 0.10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisatracurium 0.10 mg.kg(‐1)
Trial: 17426802
Drug: Cisatracurium 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisatracurium 0.15 mg.kg(‐1)
Trial: 17426802
Drug: Rocuronium 0.60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.60 mg.kg(‐1)
Trial: 17426802
Drug: Rocuronium 0.90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.90 mg.kg(‐1)
Trial: 11576567
Drug: Oral sulindac
RxNorm normalized name: Sulindac
DrugBank: Sulindac (DB00605)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sulindac (100 mg) every 12 hours until 34 weeks' gestation
Trial: 7820328
Drug: Test drug
RxNorm normalized name: URINE TEST DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test drug (piracetam)
Trial: 7820328
Drug: Reference drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference drug (piracetam)
Trial: 787460
Drug: Betahistine (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betahistine (16 mg t.i.d.)
Trial: 29280453
Drug: Topical OTD70DERM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical OTD70DERM (RGTA)
Trial: 19539211
Drug: Prochymal(R) at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prochymal(R) at a dose of either 2 or 8 million MSCs/kg in combination with corticosteroids
Trial: 19539211
Drug: Prochymal(R) at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prochymal(R) at a dose of either 2 or 8 million MSCs/kg
Trial: 16927304
Drug: Dutasteride 3.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dutasteride 3.5 mg
Trial: 3354254
Drug: Paediatric attenuated
RxNorm normalized name: varicella, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paediatric attenuated influenza vaccine (two doses, intranasally, 1 month apart)
Trial: 26222759
Drug: Aromatherapy (lavender
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatherapy (lavender oil) in addition to standard medical treatment (diclofenac sodium, 75 mg intramuscularly)
Trial: 26222759
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical therapy (diclofenac sodium, 75 mg intramuscularly)
Trial: 21443293
Drug: Combination Behavioral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination Behavioral Intervention (CBI) only
Trial: 21443293
Drug: Study medications
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study medications (naltrexone, acamprosate, naltrexone + acamprosate, placebo) with medication management (MM)